MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
expense
$22,642K
Other receivables
-$18,129K
Depreciation and
amortization
$9,957K
Accounts receivable
-$7,980K
Accounts payable
$4,782K
Inventory
-$2,702K
Operating lease,
right-of-use asset, periodic...
$1,953K
Prepaid expenses and
other current assets
-$1,945K
Other noncurrent
assets
-$282K
Deferred revenue
$77K
Net cash provided by
operating activities
$26,120K
Canceled cashflow
$44,329K
Net increase in cash
and cash...
$16,319K
Canceled cashflow
$9,801K
Accrued compensation
and other related...
-$20,956K
Net loss
-$13,470K
Accrued expenses and
other current...
-$6,136K
Operating lease liability
-$2,854K
Accrued contingent
consideration and assumed...
-$613K
Other
-$193K
Fair value
adjustments on contingent...
$57K
Other noncurrent
liabilities
-$50K
Issuance of common stock
from exercise of...
$273K
Proceeds from maturities
of marketable...
$25,000K
Net cash provided by
(used in) financing...
-$8,417K
Net cash used in
investing activities
-$1,311K
Effect of exchange
rates changes on cash...
-$73K
Canceled cashflow
$273K
Canceled cashflow
$25,000K
Payment of contingent
consideration
$8,690K
Purchases of marketable
securities
$24,714K
Purchases of property and
equipment
$1,597K
Back
Back
Cash Flow
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)
source: myfinsight.com